Recombinant RSV vaccines

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9492531
APP PUB NO 20120093847A1
SERIAL NO

13378391

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
GLAXOSMITHKLINE BIOLOGICALS SARUE DE L'INSTITUT 89 RIXENSART 1330
ID BIOMEDICAL CORPORATION OF QUEBECLAVAL QC H7V 3S8

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Baudoux, Guy Jean Marie Fernand Pierre Rixensart, BE 6 89
Blais, Normand Laval, CA 33 205
Cyr, Sonya L Belgìque, BE 2 31
Rheault, Patrick Laval, CA 16 145
Ruelle, Jean-Louis Rixensart, BE 39 151

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 15, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00